SCHEMBL4394444

SCHEMBL4394444

COC(=O)c1ccc(-c2ccc(C=C3SC(=S)N(Cc4ccc5c(c4)OCO5)C3=O)o2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.55
KMT2A Q03164 4/20 0.55
PTPN22 Q9Y2R2 2/20 0.55
MEN1 O00255 2/20 0.55
ALDH1A1 P00352 2/20 0.55
POLB P06746 2/20 0.55
MAPT P10636 2/20 0.55
MCL1 Q07820 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
PKM P14618 1/20 0.55
PTPN7 P35236 1/20 0.55
PTPN12 Q05209 1/20 0.55
STAT3 P40763 1/20 0.55
HSPD1 P10809 1/20 0.54
HSPE1 P61604 1/20 0.54
MAP3K5 Q99683 2/20 0.53
TDP1 Q9NUW8 3/20 0.51
EIF4E P06730 1/20 0.51
EIF4G1 Q04637 1/20 0.51
THRB P10828 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23171410 0.87 MEN1 (0.58) SYKKMT2APTPN22MEN1ALDH1A1
SCHEMBL4397326 0.86 SYK (0.63) SYKKMT2APTPN22MEN1ALDH1A1
SCHEMBL4397324 0.86 SYK (0.63) SYKKMT2APTPN22MEN1ALDH1A1
SCHEMBL46464 0.85 SYK (0.75) SYKKMT2APTPN22MEN1ALDH1A1
SCHEMBL23171552 0.85 SYK (0.75) SYKKMT2APTPN22MEN1ALDH1A1
SCHEMBL6742616 0.85 SYK (0.75) SYKKMT2APTPN22MEN1ALDH1A1
SCHEMBL4890213 0.83 SYK (0.57) SYKKMT2APTPN22MEN1ALDH1A1
SCHEMBL4396449 0.83 MEN1 (0.53) KMT2APTPN22MEN1ALDH1A1POLB
SCHEMBL8595362 0.83 MEN1 (0.53) KMT2APTPN22MEN1ALDH1A1POLB
SCHEMBL4890217 0.83 SYK (0.57) SYKKMT2APTPN22MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP claimed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US claimed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP claimed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO claimed
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP disclosed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP disclosed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN SYK 3137/4885KMT2A 1040/4885PTPN22 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.